Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.

摘要: Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide receptors and typically used for neuroendocrine tumours (NETs). Some the key challenges in its use are prediction efficacy toxicity, patient selection, response optimisation. In this Review, we assess current knowledge on molecular profile NETs strategies tools to predict, monitor, toxicity PRRT. The few mutations tumour genes can be evaluated (eg, ATM DAXX) limited pancreatic most likely not informative. Assays transcriptomic or based effective other cancers. A blood-based assay eight (the PRRT quotient [PPQ]) has an overall accuracy 95% predicting responses NETs. No markers exist predict Candidate include seven single nucleotide polymorphisms (SNPs) susceptible radiation. Transcriptomic evaluations blood combination gene expression specific SNPs, assessed by machine learning with algorithms tumour-specific, might yield enhance safety